BioPorto A/S (BIOPOR.CO)
| Previous close | 1.7700 |
| Open | 1.7940 |
| Bid | 1.6700 x 0 |
| Ask | 1.6800 x 0 |
| Day's range | 1.6040 - 1.7940 |
| 52-week range | 1.0020 - 4.1000 |
| Volume | |
| Avg. volume | 548,697 |
| Market cap | 562.262M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2140 |
| Earnings date | 09 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
- Globe Newswire
BioPorto Announces Interim Results for the First Six Months of 2022
August 17, 2022Announcement no. 13 BioPorto Announces Interim Results for the First Six Months of 2022 COPENHAGEN, DENMARK and BOSTON, MA, USA, August 17, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first six months of 2022 and business progress for the second quarter of 2022. Recent Highlights For the six months ending June 30, 2022: Total revenue of DKK 15.0 million / USD 2.2 million, a 23% increase over the prior yearAdjuste
- Globe Newswire
BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call
August 8, 2022News release BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call COPENHAGEN, DENMARK and BOSTON, MA, USA, August 8, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S BioPorto A/S (BioPorto) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of kidney injury, announced today that in connection with the release of its Interim Report for the second quarter of 2022, the Company’s management team will host an online investor presentation on August
- Globe Newswire
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.
COPENHAGEN, Denmark and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted subject enrollment for the third part of a 3-part clinical study to support a U.S. Food and Drug Administration (FDA) De Novo submission for use of The NGAL Test in identifying patients under the age of 22 at risk for Acute Kidney Injury (AKI). “We are very pleased to have reached the study’s planned enrollment of 600 patients by the end of Q2, as pre
